A CRISPR-Cas9-based screen of PAX5 and IKZF1 transcriptional targets identified some target genes such as NR3C1, TXNIP and CB2 as central effectors of B-lymphoid restriction of glucose and energy supply and therefore new targets for treating B-ALL [3]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.